Gene therapy of cancer in the clinic: Good news in sight from Asia?

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 5, 2007, Pages 477-482

  Favaro, Elena ^a   Indraccolo, Stefano ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Cancer; Gene therapy; Immunotherapy; Oncolytic virus; Suicide gene; Virotherapy

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GENDICINE; H 101; HERPESVIRUS VECTOR; ONCOLYTIC VIRUS; ONYX 015; PLASMID DNA; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALLOPATHY; CANCER; CANCER GENE THERAPY; CHINA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; GENE DELIVERY SYSTEM; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE TRANSFER; GENETIC ENGINEERING; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOTHERAPY; MELANOMA; REVIEW; SUICIDE GENE; SUICIDE GENE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL GENE THERAPY; VIROTHERAPY;

ANIMALS; ASIA; FORECASTING; GENE THERAPY; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 35348902601     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Gene therapy clinical trials worldwide. Journal of Gene Medicine. John Wiley and Sons Ltd, Chichester, UK (2007). http://www.wiley.co.uk/genetherapy/clinical/
2. Reid T, Warren R, Kirn D: Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther (2002) 9(12):979-986.
3. Young LS, Searle PF, Onion D, Mautner V: Viral gene therapy strategies: From basic science to clinical application. J Pathol (2006) 208(2):299-318.
4. Cross D, Burmester JK: Gene therapy for cancer treatment: Past, present and future. Clin Med Res (2006) 4(3):218-227.
5. Guo J, Xin H: Chinese gene therapy. Splicing out the West? Science (2006) 314(5803):1232-1235. •• This paper provides an excellent analysis of the recent advances in clinical gene therapy in China.
6. Peng Z: Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther (2005) 16(9):1016-1027.
7. Guinn BA, Norris JS, Huang L, Farzaneh F, Kasahara N, Deisseroth AB: International Society for Cell and Gene Therapy of Cancer (ISCGT) annual meeting: Conference overview and introduction to the symposium papers. Cancer Immunol Immunother (2006) 55(11):1406-1411. • This paper reports the most interesting findings and directions of the cancer gene therapy field reported at the International Society for Cell and Gene Therapy of Cancer meeting in 2005.
8. Human gene transfers protocols: National Institute of Health, Bethesda, MD, USA (2007). http://www4.od.nih.gov/oba/RAC/protocol.pdf
9. Edelstein ML, Abedi MR, Wixon J, Edelstein RM: Gene therapy clinical trials worldwide 1989-2004 - an overview. J Gene Med (2004) 6(6):597-602.
10. Russell SJ: Lymphokine gene therapy for cancer. Immunol Today (1990) 11(6):196-200.
11. Minuzzo S, Moserle L, Indraccolo S, Amadori A: Angiogenesis meets immunology: Cytokine gene therapy of cancer. Mol Aspects Med (2007) 28(1):59-86. • This review presents the state-of-the-art of cytokine-based gene therapy approaches for cancer.
12. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med (2004) 10(9):909-915.
13. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 6(4):295-307.
14. Laheru DA, Pardoll DM, Jaffee EM: Genes to vaccines for immunotherapy: How the molecular biology revolution has influenced cancer immunology. Mol Cancer Ther (2005) 4(11):1645-1652.
15. Engels B, Uckert W: Redirecting T lymphocyte specificity by T cell receptor gene transfer - a new era for immunotherapy. Mol Aspects Med (2007) 28(1):115-142. • This paper is an up-to-date review on the retargeting of T-cell specificity by receptor gene transfer.
16. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z et al: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 314(5796):126-129. •• This study shows therapeutic efficacy of administration of genetically engineered T-cells to patients with progressive metastatic melanoma.
17. Alemany R: Cancer selective adenoviruses. Mol Aspects Med (2007) 28(1):42-58. •• This review provides a comprehensive overview of the improvements in oncolytic virus design and critically reviews the available clinical data.
18. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274(5286):373-376.
19. Reid TR, Freeman S, Post L, McCormick F, Sze DY: Effects of ONYX-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther (2005) 12(8):673-681.
20. Yu W, Fang H: Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets (2007) 7(2):141-148.
21. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR: Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res (1997) 57(13):2559-2563.
22. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G: A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 14(1):107-117.
23. Freytag SO, Stricker H, Peabody J, Pegg J, Paielli D, Movsas B, Barton KN, Brown SL, Lu M, Kim JH: Five-year Follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther (2007) 15(3):636-642. •• This paper presents the results of a 5-year follow-up on a suicide gene therapy-based clinical trial for prostatic cancer and evidence for long-term benefit.
24. Dong F, Wang L, Davis JJ, Hu W, Zhang L, Guo W, Teraishi F, Ji L, Fang B: Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-α-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res (2006) 12(17):5224-5230.
25. Chernajovsky Y, Layward L, Lemoine N: Fighting cancer with oncolytic viruses. Br Med J (2006) 332(7534):170-172. • A critical commentary on the exploitation of oncolytic viruses for cancer gene therapy addressing safety concerns.
26. Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, Savera A, Kim JH: Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther (2007) 15(5):1016-1023.
27. Portsmouth D, Hlavaty J, Renner M: Suicide genes for cancer therapy. Mol Aspects Med (2007) 28(1):4-41. •• This review provides a clear explanation of the rationale behind the GDEPT principle, outlining the advantages and limitations of different GDEPT strategies.
28. Fillat C, Carrio M, Cascante A, Sangro B: Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: Fifteen years of application. Curr Gene Ther (2003) 3(1):13-26.
29. Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther (2000) 11(17):2389-2401.
30. Immonen A, Vapalahti M, Tyynelä K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N, Ylä-Herttuala S: AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol Ther (2004) 10(5):967-972.
31. Cerepro (siimagene ceradenovec) - treatment for brain cancer (malignant glioma): Ark Therapeutics Inc, London, UK (2007). http://www.arktherapeutics.com/main/products.php?content=products_cerepro
32. Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F, Manabe D, Thompson TC, Kumon H: Suicide gene therapy with adenoviral delivery of HSV-tk gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther (2007) 15(4):834-840. • This paper reports the safety profile and the possibility of clinical response of HSV-TK delivered by an adenoviral vector in a phase I study of hormone-refractory prostate cancer.
33. Löhr M, Hoffmeyer A, Kröger J, Freund M, Hain J, Holle A, Karle P, Knöfel WT, Liebe S, Müller P, Nizze H et al: Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet (2001) 357(9268):1591-1592.
34. Mezhir JJ, Smith KD, Posner MC, Senzer N, Yamini B, Kufe DW, Weichselbaum RR: Ionizing radiation: A genetic switch for cancer therapy. Cancer Gene Ther (2006) 13(1):1-6.
35. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 350(23):2335-2342.